Rein Therapeutics

(NASDAQ) RNTX

Current Price$1.03

Market Cap$28.88M

Since IPO (2017)-100%

5 Year-96%

1 Year-37%

1 Month-15%

Rein Therapeutics Financials at a Glance

Market Cap

$28.88M

Revenue (TTM)

$0.00

Net Income (TTM)

$49.87M

EPS (TTM)

$-1.96

P/E Ratio

-0.52

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$1.03

Volume

11,886,991.303

Open

$1.10

Price

$1.03

Volume

11,886,991.303

Open

$1.10

Previous Close

$1.03

Daily Range

$1.00 - $1.10

52-Week Range

$1.00 - $2.40

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$1.03

Volume

11,886,991.303

Open

$1.10

Previous Close

$1.03

Daily Range

$1.00 - $1.10

52-Week Range

$1.00 - $2.40

RNTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rein Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Brian J. Windsor, PhD

Website

www.reintx.com

Headquarters

Austin, TX 78758, US

RNTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-140%

Return on Capital

-1%

Return on Assets

-2%

Earnings Yield

-1.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$28.88M

Shares Outstanding

28.04M

Volume

11.89M

Avg. Volume

313.25K

Financials (TTM)

Gross Profit

$1.00K

Operating Income

$21.93M

EBITDA

$21.93M

Operating Cash Flow

$19.36M

Capital Expenditure

$0.00

Free Cash Flow

$19.36M

Cash & ST Invst.

$3.21M

Total Debt

$0.00

Rein Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$28.88M

N/A

Market Cap/Employee

$2.63M

N/A

Employees

N/A

Net Income

$31.97M

+22.0%

EBITDA

$3.87M

+90.9%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$3.21M

-75.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.06%

N/A

Return on Invested Capital

-1.22%

N/A

Free Cash Flow

$3.22M

+33.1%

Operating Cash Flow

$3.22M

+33.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BEATHeartBeam, Inc.

BEATHeartBeam, Inc.$0.88+2.76%

CELUCelularity Inc.

CELUCelularity Inc.$0.96+2.43%

QNTMQuantum BioPharma Ltd.

QNTMQuantum BioPharma Ltd.$5.55-3.14%

NOTVInotiv, Inc.

NOTVInotiv, Inc.$0.31+6.86%

TPSTTempest Therapeutics, Inc.

TPSTTempest Therapeutics, Inc.$2.04+2.51%

YI111, Inc.

YI111, Inc.$6.00-3.23%

BCABBioAtla, Inc.

BCABBioAtla, Inc.$4.27+1.43%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$99.62+0.05%

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

AAPLApple

AAPLApple$280.14+0.03%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

Questions About RNTX

What is the current price of Rein Therapeutics?

Rein Therapeutics is trading at $1.03 per share.

What is the 52-week range for Rein Therapeutics?

Over the past 52 weeks, Rein Therapeutics has traded between $1.00 and $2.40.

How much debt does Rein Therapeutics have?

As of the most recent reporting period, Rein Therapeutics reported total debt of N/A.

How much cash does Rein Therapeutics have on hand?

Rein Therapeutics reported $3.21M in cash and cash equivalents in its most recent financial results.

What is Rein Therapeutics’s dividend yield?

Rein Therapeutics does not currently have a dividend yield.

Rein Therapeutics

Rein Therapeutics Financials at a Glance

RNTX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Rein Therapeutics

RNTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Rein Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RNTX

What is the current price of Rein Therapeutics?

What is the 52-week range for Rein Therapeutics?

How much debt does Rein Therapeutics have?

How much cash does Rein Therapeutics have on hand?

What is Rein Therapeutics’s dividend yield?

Premium Investing Services